Autotelic Bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
2ndary - Private
- Investors
-
15
Autotelic Bio General Information
Description
Developer of anti-cancer drugs designed to treat cancer patients. The company focuses on developing anti-cancer drugs for selective targeting and the precise optimization of antisense oligonucleotides designed to potentially deliver greater efficacy, safety, and tolerability compared to RNA interference medicines, enabling healthcare professionals to improve the effectiveness and reduce the side effects of cancer therapies to provide treatment alternatives for cancer patients.
Contact Information
Website
www.autotelicbio.comCorporate Office
- Room 302, Building 2, Corporate Research Center, 194-41 Osongsaengmyeong 1-ro, Osong-eup
- Heungdeok-gu
- Cheongju, Chungcheongbuk 28160
- South Korea
Corporate Office
- Room 302, Building 2, Corporate Research Center, 194-41 Osongsaengmyeong 1-ro, Osong-eup
- Heungdeok-gu
- Cheongju, Chungcheongbuk 28160
- South Korea
Autotelic Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 6. Later Stage VC (Series B) | 28-Mar-2022 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC | 14-Dec-2020 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series A) | 01-Feb-2020 | Completed | Clinical Trials - Phase 3 | |||
| 3. Angel (individual) | 01-Aug-2018 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jul-2018 | Completed | Startup | |||
| 1. Seed Round | 01-Sep-2017 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Autotelic Bio Patents
Autotelic Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026141971-A1 | Pharmaceutical composition for treating fibrosis comprising sglt-2 inhibitor and angiotensin receptor blocker | Pending | 26-Dec-2024 | ||
| WO-2025234704-A1 | Pharmaceutical composition for preventing or treating cancer-related diseases comprising antisense oligonucleotide and anticancer agent as active ingredients | Pending | 07-May-2024 | ||
| WO-2025063819-A1 | Composition for treating fibrotic disease comprising thiazole derivative compound | Inactive | 21-Sep-2023 | ||
| WO-2025063820-A1 | Composition for treating pulmonary fibrosis comprising thiazole derivative compound | Inactive | 21-Sep-2023 | ||
| WO-2025063816-A1 | Composition for treating uterine fibrosis comprising thiazole derivative compound | Inactive | 21-Sep-2023 |
Autotelic Bio Signals
Autotelic Bio Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Colopl Next | Corporate Venture Capital | Minority | ||
| DreamStone Private Equity | PE/Buyout | Minority | ||
| DTN Investment (VC) | Venture Capital | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| LSK Investment | Venture Capital | Minority |
Autotelic Bio FAQs
-
When was Autotelic Bio founded?
Autotelic Bio was founded in 2015.
-
Where is Autotelic Bio headquartered?
Autotelic Bio is headquartered in Cheongju, South Korea.
-
What is the size of Autotelic Bio?
Autotelic Bio has 22 total employees.
-
What industry is Autotelic Bio in?
Autotelic Bio’s primary industry is Drug Discovery.
-
Is Autotelic Bio a private or public company?
Autotelic Bio is a Private company.
-
What is Autotelic Bio’s current revenue?
The current revenue for Autotelic Bio is .
-
How much funding has Autotelic Bio raised over time?
Autotelic Bio has raised $22.3M.
-
Who are Autotelic Bio’s investors?
Colopl Next, DreamStone Private Equity, DTN Investment (VC), Industrial Bank of Korea, and LSK Investment are 5 of 15 investors who have invested in Autotelic Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process